INCY

Business Context and Reporting Period

Company: Incyte Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2005
Business Overview: Incyte is a biotechnology company focused on the discovery and development of novel small-molecule drugs for HIV, inflammation, and cancer. The company transitioned from an information products business to a drug discovery model, closing its Palo Alto facility in 2004. As of December 31, 2005, the company had 177 employees, with 141 in research and development.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Revenues decreased 45% to $7.8 million from $14.1 million in 2004, primarily due to the discontinuation of information products and the closure of the Palo Alto facility.
• Improved Net Loss: Net loss narrowed to $103.0 million from $164.8 million in 2004. This improvement was driven by a significant reduction in restructuring charges and long-lived asset impairments compared to the prior year.
• Debt Reduction: The company repurchased $36.5 million face value of its 5.5% convertible subordinated notes during 2005, reducing total debt.
• Equity Position: Stockholders' equity moved from a positive $78.5 million in 2004 to a deficit of $(19.4) million in 2005 due to the accumulated net loss.

Guidance, Outlook, and Risks

Outlook and Management Commentary: Incyte expects to continue incurring losses for several years as it expands drug discovery and development programs. The company anticipates that revenues from information products will continue to decline and will not be a significant source of cash inflow in 2006. Management believes current cash and marketable securities are adequate to satisfy capital needs for at least the next twelve months.

Key Developments:

• Pfizer Collaboration: In November 2005, Incyte entered a collaborative agreement with Pfizer for its CCR2 antagonist portfolio. Incyte received a $40 million upfront payment in January 2006 and is eligible for up to $743 million in future milestones.
• DFC (HIV Program): Following a Phase IIb trial, the FDA requested a second Phase IIb trial (Study 204) before proceeding to Phase III. This trial was initiated in February 2006.
• Accounting Changes: The company adopted SFAS 123R (Share-Based Payment) on January 1, 2006, which is expected to increase expenses by $7.0 million to $9.0 million in 2006.

Risks and Contingencies:

• Litigation: Invitrogen Corporation is suing Incyte for patent infringement. The outcome is uncertain, and the company cannot estimate potential damages.
• Regulatory Risk: Drug development is subject to extensive FDA regulation. Failure to obtain approval for DFC or other candidates would prevent commercialization.
• Liquidity: The company has a history of operating losses and an accumulated deficit of $839.3 million. It will require additional capital in the future to fund operations.

Investor Verification Checklist

• Cash Runway: Verify if the $345 million in cash and securities is sufficient to cover the projected $100+ million annual operating burn rate and debt service obligations ($13.8 million interest due in 2006).
• DFC Regulatory Path: Confirm the status and design of the FDA-requested second Phase IIb trial (Study 204) and its impact on the timeline for Phase III.
• Pfizer Milestone Terms: Review the specific conditions required to earn the $743 million in potential milestone payments from the Pfizer collaboration.
• Invitrogen Litigation: Monitor the status of the patent infringement lawsuit and any potential settlement or judgment impacts.
• SFAS 123R Impact: Assess the actual impact of the new stock-based compensation accounting standard on 2006 earnings.